Senolytics: A Novel Strategy for Neuroprotection in ALS?

Amyotrophic lateral sclerosis (ALS) is a progressive motor neurodegenerative disease that currently has no cure and has few effective treatments. On a cellular level, ALS manifests through significant changes in the proper function of astrocytes, microglia, motor neurons, and other central nervous s...

Descripción completa

Guardado en:

Detalles Bibliográficos
Autores principales:	Alexandra Maximova, Eryn L. Werry, Michael Kassiou
Formato:	article
Lenguaje:	EN
Publicado:	MDPI AG 2021
Materias:	amyotrophic lateral sclerosis senescence senolytics neurodegenerative disease Biology (General) QH301-705.5 Chemistry QD1-999
Acceso en línea:	https://doaj.org/article/337823380b344cbeb83fcaaed13ab187
Etiquetas:	Agregar Etiqueta Sin Etiquetas, Sea el primero en etiquetar este registro!

id	oai:doaj.org-article:337823380b344cbeb83fcaaed13ab187
record_format	dspace
spelling	oai:doaj.org-article:337823380b344cbeb83fcaaed13ab1872021-11-11T17:28:23ZSenolytics: A Novel Strategy for Neuroprotection in ALS?10.3390/ijms2221120781422-00671661-6596https://doaj.org/article/337823380b344cbeb83fcaaed13ab1872021-11-01T00:00:00Zhttps://www.mdpi.com/1422-0067/22/21/12078https://doaj.org/toc/1661-6596https://doaj.org/toc/1422-0067Amyotrophic lateral sclerosis (ALS) is a progressive motor neurodegenerative disease that currently has no cure and has few effective treatments. On a cellular level, ALS manifests through significant changes in the proper function of astrocytes, microglia, motor neurons, and other central nervous system (CNS) cells, leading to excess neuroinflammation and neurodegeneration. Damage to the upper and lower motor neurons results in neural and muscular dysfunction, leading to death most often due to respiratory paralysis. A new therapeutic strategy is targeting glial cells affected by senescence, which contribute to motor neuron degeneration. Whilst this new therapeutic approach holds much promise, it is yet to be trialled in ALS-relevant preclinical models and needs to be designed carefully to ensure selectivity. This review summarizes the pathways involved in ALS-related senescence, as well as known senolytic agents and their mechanisms of action, all of which may inform strategies for ALS-focused drug discovery efforts.Alexandra MaximovaEryn L. WerryMichael KassiouMDPI AGarticleamyotrophic lateral sclerosissenescencesenolyticsneurodegenerative diseaseBiology (General)QH301-705.5ChemistryQD1-999ENInternational Journal of Molecular Sciences, Vol 22, Iss 12078, p 12078 (2021)
institution	DOAJ
collection	DOAJ
language	EN
topic	amyotrophic lateral sclerosis senescence senolytics neurodegenerative disease Biology (General) QH301-705.5 Chemistry QD1-999
spellingShingle	amyotrophic lateral sclerosis senescence senolytics neurodegenerative disease Biology (General) QH301-705.5 Chemistry QD1-999 Alexandra Maximova Eryn L. Werry Michael Kassiou Senolytics: A Novel Strategy for Neuroprotection in ALS?
description	Amyotrophic lateral sclerosis (ALS) is a progressive motor neurodegenerative disease that currently has no cure and has few effective treatments. On a cellular level, ALS manifests through significant changes in the proper function of astrocytes, microglia, motor neurons, and other central nervous system (CNS) cells, leading to excess neuroinflammation and neurodegeneration. Damage to the upper and lower motor neurons results in neural and muscular dysfunction, leading to death most often due to respiratory paralysis. A new therapeutic strategy is targeting glial cells affected by senescence, which contribute to motor neuron degeneration. Whilst this new therapeutic approach holds much promise, it is yet to be trialled in ALS-relevant preclinical models and needs to be designed carefully to ensure selectivity. This review summarizes the pathways involved in ALS-related senescence, as well as known senolytic agents and their mechanisms of action, all of which may inform strategies for ALS-focused drug discovery efforts.
format	article
author	Alexandra Maximova Eryn L. Werry Michael Kassiou
author_facet	Alexandra Maximova Eryn L. Werry Michael Kassiou
author_sort	Alexandra Maximova
title	Senolytics: A Novel Strategy for Neuroprotection in ALS?
title_short	Senolytics: A Novel Strategy for Neuroprotection in ALS?
title_full	Senolytics: A Novel Strategy for Neuroprotection in ALS?
title_fullStr	Senolytics: A Novel Strategy for Neuroprotection in ALS?
title_full_unstemmed	Senolytics: A Novel Strategy for Neuroprotection in ALS?
title_sort	senolytics: a novel strategy for neuroprotection in als?
publisher	MDPI AG
publishDate	2021
url	https://doaj.org/article/337823380b344cbeb83fcaaed13ab187
work_keys_str_mv	AT alexandramaximova senolyticsanovelstrategyforneuroprotectioninals AT erynlwerry senolyticsanovelstrategyforneuroprotectioninals AT michaelkassiou senolyticsanovelstrategyforneuroprotectioninals
_version_	1718432055133470720

Senolytics: A Novel Strategy for Neuroprotection in ALS?

Ejemplares similares